Our results are consistent with an RCT by Elgindy et al. of 100 premenopausal breast cancer patients, which showed no differences in menstruation resumption rates or hormonal and ultrasound markers between the treatment (GnRH-a) and control groups [19]. Here, GNRH1 is linked to breast cancer.